Roche launches US$500 mln manufacturing arm in Singapore

Roche, a Swiss drug-making firm, specializes in research-focused healthcare particularly in the areas of pharmaceuticals and diagnostics. The company opened its first biologics manufacturing site in the Asia Pacific region in Tuas yesterday.

Its two facilities cost Roche US$500 million and will be used to produce drugs Avastin and Lucentis. Avastin is a targeted cancer therapy which treats various tumour types such as colorectal cancer, lung cancer, breast cancer, brain cancer and renal cell carcinoma, while Lucentis is used to treat patients with wet age-related macular degeneration, a leading cause of blindness in people over 55.

On the selection of Singapore, Dr Patrick Y. Yang, Executive Vice President of Genentech Technical Operations, which is a wholly-owned member of Roche Group stated: “As we supply a global market, Singapore offers important advantages to Roche’s manufacturing network, including a skilled labor pool, nearby biotechnology expertise and a supportive business environment.”

Finance Minister Mr Tharman Shanmugaratnam, who was also at the opening ceremony, said: “Singapore is proud to be Roche’s first site for biologics manufacturing in Asia. The site expresses a number of things that are making Singapore's future – cutting-edge manufacturing technologies, the commercialisation of science, a commitment to develop a top-quality workforce and the deepening partnerships that leading global players are forging with Singapore.” He added that Singapore was committed to building its biologics manufacturing sector, with six plants so far set up in the last four years. When these are fully operational, they are expected to create over 1,000 jobs for employees.